share_log

Ascendiant Capital Initiates Coverage On NRX Pharmaceuticals With Buy Rating, Announces Price Target of $4

Benzinga Real-time News ·  Nov 9, 2022 19:25

Ascendiant Capital analyst Edward Woo initiates coverage on NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy rating and announces Price Target of $4.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment